Quintrio
Home

WHOLESALE-DRUGS, PROPRIETARIES & DRUGGISTS' SUNDRIES

McKesson Corporation

MCK

McKesson is one of three leading pharmaceutical wholesalers in the US engaged in sourcing and distributing branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with Cencora and Cardinal Health, the three account for over 90% of the US pharmaceutical wholesale industry. Outside the US market, McKesson engages in pharmaceutical wholesale and distribution in Canada. Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.

Last trade $1,092.35
Day change -$12.695 (-1.15%)
Day range $1,090.19 – $1,114.78
Volume 284,394
Market cap $127.58B

Open XNYS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$127.58B
Price / earnings
27.15×
Price / book
-32.27×
Price / sales
0.3×
EV / sales
0.31×
EV / EBITDA
16.73×

Profitability

Earnings per share
$40.71
Return on assets
5.09%
Return on equity
-118.87%
Dividend yield
0.31%

Liquidity and leverage

Debt / equity
-2.33×
Current ratio
0.9×
Quick ratio
0.52×
Cash ratio
0.09×

Cash flow

Price / cash flow
17×
Price / free cash flow
17.95×
Free cash flow
$7.11B

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for MCK, quarterly periods
Line itemQ2 FY2027 Sep 30, 2026Q1 FY2027 Jun 30, 2026Q4 FY2026 Mar 31, 2026Q3 FY2026 Dec 31, 2025Q2 FY2026 Sep 30, 2025Q1 FY2026 Jun 30, 2025Q4 FY2025 Mar 31, 2025Q3 FY2025 Dec 31, 2024
Revenue$110.96B$105.38B$96.3B$106.16B$103.15B$97.83B$90.82B$95.29B
Cost of revenue$107B$101.7B$92.25B$102.47B$99.61B$94.55B$87.18B$92.01B
Gross profit$3.96B$3.69B$4.04B$3.69B$3.54B$3.28B$3.64B$3.28B
Selling, general and administrative$2.27B$2.26B$1.8B$2.03B$2.07B$2.2B$1.98B$2.03B
Research and development$0$0$0$0$0$0$0$0
Total operating expenses$2.35B$2.37B$1.89B$2.07B$2.14B$2.24B$2.05B$2.06B
Operating income$1.6B$1.32B$2.15B$1.62B$1.41B$1.04B$1.59B$1.22B
Interest expense-$105M-$77M-$61M-$63M-$74M-$49M-$45M-$67M
Income before taxes$1.56B$1.31B$2.13B$1.63B$1.4B$1.05B$1.52B$1.23B
Income taxes$266M$276M$270M$380M$232M$220M$209M$298M
Net income$1.3B$1.03B$1.86B$1.25B$1.16B$831M$1.31B$928M
Net income attributable to common shareholders$1.22B$614M$1.68B$1.19B$1.11B$784M$1.26B$879M
EBITDA$1.88B$1.62B$2.44B$1.84B$1.66B$1.24B$1.82B$1.41B
Basic earnings per share$10.47$5.17$13.81$9.59$8.95$6.28$10.12$6.95
Diluted earnings per share$10.44$5.15$13.64$9.63$8.92$6.25$9.97$6.98

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Here is What to Know Beyond Why McKesson Corporation (MCK) is a Trending Stock

McKesson (MCK), a prescription drug distributor, has gained 12.6% over the past month, outperforming the S&P 500's -3.7% decline. The company has a Zacks Rank #2 (Buy) rating based on positive earnings estimate revisions. Current quarter EPS is expected at $10.79 (+15.5% YoY), with full-year earnings projected at $45.78 (+17.1% YoY). Revenue growth is forecasted at 8% for the current quarter and fiscal year. McKesson has consistently beaten consensus estimates and trades at a valuation discount to peers (Value Style Score: B).

The Motley Fool

Johnson & Johnson vs. Eli Lilly: Which Healthcare Giant's Stock Is a Better Buy for 2027?

The article compares two pharmaceutical giants for 2027 investment. Johnson & Johnson offers stability with a 6% revenue growth, lower P/E ratio of 42.59, and strong free cash flow of $19.7B, but faces patent expirations and litigation risks. Eli Lilly demonstrates explosive 44.7% revenue growth driven by GLP-1 drugs like Mounjaro and Zepbound, commanding a premium valuation (P/E 47.05), with significant future growth potential but concentrated revenue dependency.

Zacks Investment Research

3 Reasons Why Growth Investors Shouldn't Overlook McKesson (MCK)

McKesson (MCK) is highlighted as an attractive growth stock with a Zacks Growth Score of A and Zacks Rank #2 (Buy). The prescription drug distributor demonstrates strong fundamentals including projected 17% EPS growth (vs. 5.3% industry average), superior asset utilization ratio of 4.83, and positive earnings estimate revisions with a 3.2% upward surge over the past month.

Zacks Investment Research

McKesson (MCK) Upgraded to Buy: Here's What You Should Know

McKesson (MCK) has been upgraded to a Zacks Rank #2 (Buy) rating due to upward trends in earnings estimates. The prescription drug distributor's Zacks Consensus Estimate has increased 1.5% over the past three months, positioning it in the top 20% of Zacks-covered stocks for estimate revisions. The upgrade suggests potential near-term stock price appreciation based on improving business fundamentals.

Zacks Investment Research

Here's What Key Metrics Tell Us About McKesson (MCK) Q2 Earnings

McKesson reported $110.96 billion in revenue for Q3 2026, up 7.6% year-over-year and beating consensus estimates by 0.77%. EPS of $11.68 exceeded expectations of $10.69 by 9.26%. The company showed strong performance across most business segments, particularly in Oncology & Multispecialty and Prescription Technology Solutions, though Medical-Surgical Solutions operating profit fell short of estimates.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily
Declared upcoming dividend $0.94 per share
Declared
Oct 20, 2026
Ex-dividend
Dec 1, 2026
Pay date
Jan 4, 2027
Ex-dividendAmount / sharePay dateType
Sep 1, 2026$0.94Oct 1, 2026recurring
Jun 1, 2026$0.82Jul 1, 2026recurring
Mar 2, 2026$0.82Apr 1, 2026recurring
Dec 1, 2025$0.82Jan 2, 2026recurring
Sep 2, 2025$0.82Oct 1, 2025recurring

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.